{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:05:59Z","timestamp":1793300759980,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001732","name":"Danmarks Grundforskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jhepr.2021.100317","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T05:47:31Z","timestamp":1625896051000},"page":"100317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Determining a healthy reference range and factors potentially influencing PRO-C3 \u2013 A biomarker of liver fibrosis"],"prefix":"10.1016","volume":"3","author":[{"given":"Elisabeth","family":"Erhardtsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.K.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Julie","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Shevell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100317_bib1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100317_bib2","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1080\/10408398.2018.1458021","article-title":"Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: synbiotic supplementation and NAFLD","volume":"59","author":"Hadi","year":"2019","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.jhepr.2021.100317_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-0031-1276643","article-title":"Genetics of alcoholic and nonalcoholic fatty liver disease","volume":"31","author":"Anstee","year":"2011","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100317_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100317_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2021.100317_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100317_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100317_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100317_bib14","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100317_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2021.100317_bib16","series-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment guidance for industry","year":"2018"},{"key":"10.1016\/j.jhepr.2021.100317_bib17","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jhepr.2021.100317_bib18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2337\/dc18-2578","article-title":"Use of plasma fragments of propeptides of Type III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2021.100317_bib19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100317_bib20","series-title":"Algorithm for predicting advanced NASH fibrosis on screening biopsy in resmetirom phase 3 MAESTRO-NASH clinical trial","author":"Harrison","year":"2020"},{"key":"10.1016\/j.jhepr.2021.100317_bib21","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100317_bib22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany","volume":"48","author":"Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2021.100317_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100317_bib24","series-title":"Guideline on bioanalytical method validation","year":"2012"},{"key":"10.1016\/j.jhepr.2021.100317_bib25","series-title":"Evaluation of Stability of In\u00a0Vitro Diagnostic Reagents","year":"2009"},{"key":"10.1016\/j.jhepr.2021.100317_bib26","unstructured":"BS EN ISO 23640:2015 In vitro diagnostic medical devices. Evaluation of stability of in vitro diagnostic reagents."},{"key":"10.1016\/j.jhepr.2021.100317_bib27","series-title":"Interference Testing in Clinical Chemistry; Approved Guideline","year":"2005"},{"key":"10.1016\/j.jhepr.2021.100317_bib28","series-title":"Evaluation of Precision of Quantitative Measurement Procedures","year":"2014"},{"key":"10.1016\/j.jhepr.2021.100317_bib29","series-title":"CLSI C28-A3c Vol. 28 No. 30. Defining, Establishing and Verifying Reference Intervals in The Clinical Laboratory; Approved Guideline","year":"2010"},{"key":"10.1016\/j.jhepr.2021.100317_bib30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.jhepr.2021.100317_bib31","series-title":"An introduction to dplR","author":"Bunn","year":"2020"},{"key":"10.1016\/j.jhepr.2021.100317_bib32","series-title":"Package \u2018referenceIntervals\u2019 Type Package Title Reference Intervals","author":"Maintainer","year":"2020"},{"key":"10.1016\/j.jhepr.2021.100317_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jhepr.2021.100317_bib34","series-title":"Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","year":"2018"},{"key":"10.1016\/j.jhepr.2021.100317_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH \u2014 current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non-invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100317_bib37","doi-asserted-by":"crossref","first-page":"12414","DOI":"10.1038\/s41598-018-30457-y","article-title":"An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis","volume":"8","author":"Luo","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100317_bib38","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/apt.15427","article-title":"Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program","volume":"50","author":"Huber","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2021.100317_bib39","article-title":"Plasma collagen type III (PRO-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study","author":"Leeming","year":"2017","journal-title":"NASH Biomarkers Work"},{"key":"10.1016\/j.jhepr.2021.100317_bib40","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients\u00a0with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100317_bib41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100317_bib42","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2021.100317_bib43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib44","unstructured":"The Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project. https:\/\/litmus-project.eu\/."},{"key":"10.1016\/j.jhepr.2021.100317_bib46","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100317_bib47","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","article-title":"A\u00a0sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients","volume":"116","author":"Eslam","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100317_bib48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100317_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:27:53Z","timestamp":1762900073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2589555921000938"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100317","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining a healthy reference range and factors potentially influencing PRO-C3 \u2013 A biomarker of liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100317"}}